Specific hypomethylated CpGs at the IGF2 locus act as an epigenetic biomarker for familial adenomatous polyposis colorectal cancer

Epigenomics

Volumn 2, Issue 3, 2010, Pages 365-375

  Miroglio, Audrey ^a   Jammes, Hélne ^b   Tost, Jrg ^c   Ponger, Loc ^d   Gut, Ivo Glynne ^c   Abdalaoui, Hafida El ^c   Coste, Jol ^e   Chaussade, Stanislas ^e   Arimondo, Paola B ^d   Lamarque, Dominique ^f   Dandolo, Luisa ^a  

^a INSTITUT COCHIN   (France)

^b ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^c CENTRE NATIONAL DE GÉNOTYPAGE   (France)

^d MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

^e Institut Cochin   (France)

^f HÔTEL DIEU   (France)

Author keywords

colorectal cancer; DNA methylation; epigenetics; lymphocytes; pyrosequencing

Indexed keywords

BIOLOGICAL MARKER; GENOMIC DNA; RNA;

ADENOMATOUS POLYP; ADULT; ARTICLE; CANCER DIAGNOSIS; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EARLY DIAGNOSIS; EPIGENETICS; FAMILIAL CANCER; FAMILIAL POLYPOSIS; GENETIC MARKER; HUMAN; HUMAN CELL; LYMPHOCYTE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; QUANTITATIVE ANALYSIS;

ADENOMATOUS POLYPOSIS COLI; BIOLOGICAL MARKERS; CLUSTER ANALYSIS; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; FRANCE; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LYMPHOCYTES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; SULFITES;

EID: 77954107939     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.10.24     Document Type: Article

References (39)

1. Matsuzaki K, Deng G, Tanaka H, Kakar S, Miura S, Kim YS: The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin. Cancer Res. 11(24 Pt 1), 8564-8569 (2005).
2. Issa JP: CpG island methylator phenotype in cancer. Nat. Rev. Cancer 4(12), 988-993 (2004).
3. Feinberg AP, Cui H, Ohlsson R: DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. Semin. Cancer Biol. 12(5), 389-398 (2002).
4. Gabory A, Ripoche MA, Yoshimizu T, Dandolo L: The H19 gene: regulation and function of a non-coding RNA. Cytogenet. Genome Res. 113(1-4), 188-193 (2006).
5. Hao Y, Crenshaw T, Moulton T, Newcomb E, Tycko B: Tumour-suppressor activity of H19 RNA. Nature 365(6448), 764-767 (1993).
6. Yoshimizu T, Miroglio A, Ripoche MA et al.: The H19 locus acts in vivo as a tumor suppressor. Proc. Natl Acad. Sci. USA 105(34), 12417-12422 (2008).
7. Leighton PA, Saam JR, Ingram RS, Stewart CL, Tilghman SM: An enhancer deletion affects both H19 and Igf2 expression. Genes Dev. 9(17), 2079-2089 (1995).
8. Reik W, Walter J: Genomic imprinting: parental infuence on the genome. Nat. Rev. Genet. 2(1), 21-32 (2001).
9. Murrell A, Ito Y, Verde G et al.: Distinct methylation changes at the IGF2-H19 locus in congenital growth disorders and cancer. PLoS ONE 3(3), E1849 (2008).
10. Reik W, Brown KW, Schneid H, Le Bouc Y, Bickmore W, Maher ER: Imprinting mutations in the Beckwith-Wiedemann syndrome suggested by altered imprinting pattern in the IGF2-H19 domain. Hum. Mol. Genet. 4(12), 2379-2385 (1995).
11. Schneid H, Seurin D, Vazquez MP, Gourmelen M, Cabrol S, Le Bouc Y: Parental allele specifc methylation of the human insulin-like growth factor II gene and Beckwith-Wiedemann syndrome. J. Med. Genet. 30(5), 353-362 (1993).
12. Tremblay KD, Saam JR, Ingram RS, Tilghman SM, Bartolomei MS: A paternal-specifc methylation imprint marks the alleles of the mouse H19 gene. Nat. Genet. 9(4), 407-413 (1995).
13. Vu TH, Li T, Nguyen D et al.: Symmetric and asymmetric DNA methylation in the human IGF2-H19 imprinted region. Genomics 64(2), 132-143 (2000).
14. Zhang Y, Shields T, Crenshaw T, Hao Y, Moulton T, Tycko B: Imprinting of human H19: allele-specifc CPG methylation, loss of the active allele in Wilms tumor, and potential for somatic allele switching. Am. J. Hum. Genet. 53(1), 113-124 (1993).
15. Kinouchi Y, Hiwatashi N, Higashioka S, Nagashima F, Chida M, Toyota T: Relaxation of imprinting of the insulin-like growth factor II gene in colorectal cancer. Cancer Lett. 107(1), 105-108 (1996).
16. Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP: Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat. Med. 4(11), 1276-1280 (1998).
17. Cui H, Cruz-Correa M, Giardiello FM et al.: Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299(5613), 1753-1755 (2003).
18. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP: Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res. 62(22), 6442-6446 (2002).
19. Ito Y, Koessler T, Ibrahim AE et al.: Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. Hum. Mol. Genet. 17(17), 2633-2643 (2008).
20. Hisamuddin IM, Yang VW: Genetics of colorectal cancer. MedGenMed. 6(3), 13 (2004).
21. Jo WS, Chung DC: Genetics of hereditary colorectal cancer. Semin. Oncol. 32(1), 11-23 (2005).
22. Dupont JM, Tost J, Jammes H, Gut IG: De novo quantitative bisulfte sequencing using the pyrosequencing technology. Anal. Biochem. 333(1), 119-127 (2004).
23. Tost J, El Abdalaoui H, Gut IG: Serial pyrosequencing for quantitative DNA methylation analysis. Biotechniques 40(6), 721-722, 724, 726 (2006).
24. El-Naggar AK, Lai S, Tucker SA et al.: Frequent loss of imprinting at the IGF2 and H19 genes in head and neck squamous carcinoma. Oncogene 18(50), 7063-7069 (1999).
25. Dejeux E, Olaso R, Dousset B et al.: Hypermethylation of the IGF2 differentially methylated region 2 is a specifc event in insulinomas leading to loss-of-imprinting and overexpression. Endocr. Relat. Cancer 16(3), 939-952 (2009).
26. Korshunova Y, Maloney RK, Lakey N et al.: Massively parallel bisulphite pyrosequencing reveals the molecular complexity of breast cancer-associated cytosine-methylation patterns obtained from tissue and serum DNA. Genome Res. 18(1), 19-29 (2008).
27. Tost J, Gut IG: DNA methylation analysis by pyrosequencing. Nat. Protoc. 2(9), 2265-2275 (2007).
28. De La Chapelle A: Genetic predisposition to colorectal cancer. Nat. Rev. Cancer 4(10), 769-780 (2004).
29. Eden A, Gaudet F, Waghmare A, Jaenisch R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300(5618), 455 (2003).
30. Feinberg AP: Alterations in DNA methylation in colorectal polyps and cancer. Prog. Clin. Biol. Res. 279, 309-317 (1988).
31. Jones PA, Baylin SB: The epigenomics of cancer. Cell 128(4), 683-692 (2007).
32. Robertson KD: DNA methylation and human disease. Nat. Rev. Genet. 6(8), 597-610 (2005).
33. Nakagawa H, Chadwick RB, Peltomaki P, Plass C, Nakamura Y, De La Chapelle A: Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc. Natl Acad. Sci. USA 98(2), 591-596 (2001).
34. Cheng Y, Idrees K, Shattock R et al.: Loss of imprinting and marked gene elevation are two forms of aberrant IGF2 expression in colorectal cancer. Int. J. Cancer (2009) (Epub ahead of print).
35. Scelfo RA, Schwienbacher C, Veronese A et al.: Loss of methylation at chromosome 11p15.5 is common in human adult tumors. Oncogene 21(16), 2564-2572 (2002).
36. Cui H, Niemitz EL, Ravenel JD et al.: Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site. Cancer Res. 61(13), 4947-4950 (2001).
37. Steenman MJ, Rainier S, Dobry CJ, Grundy P, Horon IL, Feinberg AP: Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat. Genet. 7(3), 433-439 (1994).
38. Lopes S, Lewis A, Hajkova P et al.: Epigenetic modifcations in an imprinting cluster are controlled by a hierarchy of DMRs suggesting long-range chromatin interactions. Hum. Mol. Genet. 12(3), 295-305 (2003).
39. Kaneda A, Wang CJ, Cheong R et al.: Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc. Natl Acad. Sci. USA 104(52), 20926-20931 (2007).